We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
'Revolution Race Cars' is the brainchild of a team of British designers, engineers, and industry specialists. The company has produced an all-new race car: Revolution A-One that challenges not only the status quo but also changes the postcode. The car is created after eighteen months of R&D, rigorous selection, and 4,000 miles of extreme testing of Revolution's suppliers and partners. The official production of Revolution A-One started in May 2019, and its sales have already been recorded in three countries. With the proceeds, the company will optimise its production cycle for future expansion.
days to go: Expired investment: £392,220
Glovebox Direct is an online automotive parts, accessories and merchandise marketplace selling original equipment direct from the car and bike brands.
days to go: Expired investment: £181,670
ImpactRI have created a collaborative descision making system called QIARK which helps to make complex decisions simple. QIARK aims to bridge the gap between data and actionable decisions and the intelligent system can facilitate to anyone interested in a particular problem and provide an unbiased and real intelligent solution. 
days to go: Expired investment: £149,720
Amino focuses on targeted nutrition using amino acids to improve human health, emphasizing the untapped potential beyond sports and bodybuilding. Currently offering pre- and intra-workout amino acid drinks, the company aims to expand its product line to cater to a broader consumer base, believing the market lacks variety in ready-to-mix powdered blends. Backed by scientific research and a commitment to taste and accessibility, Amino aspires to emerge as the leading global brand in amino acid products.
days to go: Expired investment: £193,219
Actve is on a mission to change the way people connect with their favourite fitness creators. The company aspires to help creators earn an income and build a subscription business. Actve asserts that it caters to a variety of creator needs allowing them to live-stream their workouts, offer guided programs to customers, or use Actve's software to manage their clients. The company aims to become a contender in the digital fitness market that is projected to be worth £21 billion by 2022. It aims to launch its platform in September 2021. Actve will use the investment to develop its platform, hire key staff, build its user base, and work towards becoming an industry champion for fitness creators.
days to go: Expired investment: £165,627
&SISTERS is a femcare company offering products that are hypoallergenic, pH-neutral and free from chlorine, pesticides & perfumes. It has sold 225,000+ certified organic cotton period products, directly to 300+ customers. The company has many listed retailers including Feel Unique, Farmdrop and Triyoga and exports to many countries including Asia and Europe. In January 2020, &SISTERS is planning to launch a new paper-wrapped naked tampon®. With the proceeds, the company will expand the product range, expand the team, raise awareness and accelerate sales.
days to go: Expired investment: £199,630
Please watch the video for more information
days to go: Expired investment: £376,618
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph